Search results for: Market Access
Filter search results
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…more willing to prescribe biosimilars in those therapeutic areas within two to three years after introduction, they estimate. Marketing penetration, expected to be below 5% of market share initially, then…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
…patients with ‘fair access’ to that drug? This paper from ICER and OHE authors seeks to define fair access. It proposes Ethical Goals for Access and Fair Design Criteria for…
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…VP of Global Value and Access at Amgen, discussed the four policy domains that need to be addressed to improve access to CTs: the incentive problem, the implementation problem, competition…
Narrowing the Gap between provision and need for medicines in developing countries
1 February 2000
…would permit companies to extend market exclusivity for any of their approved products in exchange for marketing an approved LDC drug at affordable prices. A guaranteed purchase fund, such as…
The Spanish Medicines Market Today
9 February 2011
…market authorisation, pricing and reimbursement for medicines still are decided at national level, regions have been implementing their own policies intended to affect demand and shape the market. The change…
Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation
21 February 2020
People living in Middle and Low Income Countries (MLICs) do not get access to innovative treatments and new treatments meeting MLIC requirements do not come to market. These issues should…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…to a drug with a fair, value-based price. But how do we define fair access? This paper from ICER and OHE authors develops a fair access framework, proposing Ethical Goals…
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
…that compares the availability of and access to orphan medicinal products (OMPs) in the UK (England, Scotland and Wales), France, Germany, Italy and Spain. The analysis quantifies the availability, access and the time…
Canberra Hypothesis: the Economics of the Prescription Medicine Market
1 July 1975
…carefully the relative merits and the relative price of the alternatives in the market. The paper argued that price competition operated in the prescription medicine market just as it does…